Thus, MIB/MS analysis identified MEK and IKKα as important downstream targets of Lyn, suggesting that co-targeting these kinases may provide a unique strategy to inhibit Lyn-dependent imatinib-resistant CML. The gene discussed is CHUK; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.